IGC Pharma Inc

For the period ended Mar 31, 2024. Filed Jun 24, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jun 24, 2024

IGC$0.20-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

CONSOLIDATED STATEMENT OF STOCKHOLDERS’** EQUITY**

(in thousands)

	Number of Common Shares	Common Stock and Additional Paid in Capital ($)	Accumulated Deficit ($)	Accumulated Other Comprehensive Loss ($)	Total Stockholders’ Equity ($)
Balances as of April 1, 2022	51,054	116,019	(89,159)	(2,968)	23,892
Common stock-based compensation & expenses, net	1,815	2,843	-	-	2,843
Issuance of common stock through offering (net of expenses)	208	103	-	-	103
Cancellation/forfeiture of shares	-	-	-	-	-
Common stock subscribed	-	-	-	-	-
Net loss	-	-	(11,506)	-	(11,506)
Foreign currency translation adjustments	-	-	-	(421)	(421)
Balances as of March 31, 2023	53,077	118,965	(100,665)	(3,389)	14,911
Balances as of April 1, 2023	53,077	118,965	(100,665)	(3,389)	14,911
Common stock-based compensation & expenses, net	3,534	1,917	-	-	1,917
Issuance of common stock through offering (net of expenses)	10,580	3,027	-	-	3,027
Cancellation/forfeiture of shares	(500)	-	-	-	-
Common stock subscribed	-	500	-	-	500
Net loss	-	-	(13,000)	-	(13,000)
Foreign currency translation adjustments	-	-	-	(34)	(34)
Balances as of March 31, 2024	66,691	124,409	(113,665)	(3,423)	7,321

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.